PLXP VS APVO Stock Comparison
Performance
PLXP10/100
10/100
PLXP returned -96.94% in the last 12 months. Based on the other stocks in its sector with an average return of -31.58%, its performance is below average giving it a grade of 10 of 100.
APVO10/100
10/100
APVO returned -89.87% in the last 12 months. Based on SPY's performance of -20.61%, its performance is below average giving it a score of 10 of 100.
Forecast
PLXP75/100
75/100
1 analysts offer 12-month price forecasts for PLXP. Together, they have an average target of 0, the most optimistic forecast put PLXP at 0 within 12-months and the most pessimistic has PLXP at 0.
APVO
"Forecast" not found for APVO
Sentiment
PLXP71/100
71/100
PLXP had a bullish sentiment score of 70.81% across Twitter and StockTwits over the last 12 months. It had an average of 9.26 posts, 0.97 comments, and 3.56 likes per day.
APVO67/100
67/100
APVO had a bullish sentiment score of 66.58% across Twitter and StockTwits over the last 12 months. It had an average of 13.07 posts, 7.32 comments, and 21.67 likes per day.
Technicals
PLXP10/100
10/100
PLXP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
APVO11/100
11/100
APVO receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
PLXP10/100
10/100
PLXP has missed earnings 9 times in the last 20 quarters.
APVO10/100
10/100
APVO has missed earnings 6 times in the last 20 quarters.
Profit
PLXP41/100
41/100
Out of the last 20 quarters, PLXP has had 8 profitable quarters and has increased their profits year over year on 6 of them.
APVO19/100
19/100
Out of the last 20 quarters, APVO has had 3 profitable quarters and has increased their profits year over year on 3 of them.
Volatility
PLXP30/100
30/100
PLXP has had a lower than average amount of volatility over the last 12 months giving it a grade of 29 of 100.
APVO36/100
36/100
APVO has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.
Analyst Price Targets
PLXP
"Analyst Price Targets" not found for PLXP
APVO75/100
75/100
1 analysts offer 12-month price targets for APVO. Together, they have an average target of 0, the most optimistic target put APVO at 0 within 12-months and the most pessimistic has APVO at 0.
All score calculations are broken down here to help you make more informed investing decisions
PLx Pharma Inc. Common Stock Summary
Nasdaq / PLXP
Healthcare
Drug Manufacturers—Specialty & Generic
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Aptevo Therapeutics Inc Summary
Nasdaq / APVO
Healthcare
Biotechnology
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PLXP to other companies in the same or a similar industry.